Mar 14, 2024 / 02:00PM GMT
Operator
Good morning, ladies and gentlemen. Thank you for standing by, and welcome to the UroGen Pharma full year 2023 earnings call. Please be advised that today's conference is being recorded I would now like to hand the conference over to your speaker today, Vincent Perrone, Head of Investor Relations. You may begin.
Vincent I. Perrone UroGen Pharma Limited-Senior Director - IR
Thank you, operator. Good morning, everyone, and welcome to UroGen Pharma's full year 2023 financial results and business update conference call. Earlier this morning, we issued a press release providing an overview of our recent corporate highlights and financial results for the quarter and year ended December 31, 2023.
The press release can be accessed on the Investors portion of our website at investors.urogen.com. Joining me on the call today are Liz Barrett, our President and Chief Executive Officer; Dr. Mark Schoenberg, Chief Medical Officer; Jeff Bova, our Chief Commercial Officer; and Don Kim, Chief Financial Officer.
During today's call, we will be
Q4 2023 Urogen Pharma Ltd Earnings Call Transcript
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot